-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
recently evaluated the effectiveness and safety of the oral Janus kinase 1 selective inhibitor Upadacitinib asulcerative colitis(UC) induction therapythe multicenter, double-blind, 2b study involving 250 patients with moderate to severe active UC patients who had inadequate or intolerable response to corticosteroids,immuno
inhibitors and/or biological therapy, and randomly received placebo or Upadacitinib-induced therapy (7.5 mg, 15 mg, 30 mg or 45 mg, slow interpretation), one day, 8 weeks of treatmentThe main endpoint of the study was the proportion of participants who reached clinical remission in week 8 based on the Mayo scorein week 8, patients in the 7.5mg, 15mg, 30mg or 45mg Upadacitinib treatment group received clinical remission in 8.5%, 14.3%, 13.5% and 19.6% of patients, respectively, while patients with placebo received clinical remissionAt week 8, the endoscopic improvement rates were 14.9%, 30.6%, 26.9% and 35.7% in patients who received Upadacitinib 7.5 mg, 15 mg, 30 mg or 45 mg, respectively, compared with 2.2% in the placebo groupThe 45 mg Upadacitinib group reported 1 case of shingles and 1 case of pulmonary embolism accompanied by deep veinthrombosis(diagnosed 26 days after treatment discontinuation)Upadacitinib treatment can lead to elevated blood lipid levels and phosphoric acid kinasein Phase 2b trials, 8 weeks of Upadacitinib treatment can effectively induce patients with moderate to severe active ulcerative colitis to obtain disease relief
